Male Hypogonadism Market Share, Trends & Forecast - 2022 - PowerPoint PPT Presentation

Loading...

PPT – Male Hypogonadism Market Share, Trends & Forecast - 2022 PowerPoint presentation | free to download - id: 864a06-NTdhY



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Male Hypogonadism Market Share, Trends & Forecast - 2022

Description:

Male Hypogonadism Market report, published by Allied Market Research forecasts that the global market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, growing at a CAGR of 3.1% from 2016 to 2022. The pituitary disorders segment accounted for nearly half of the total market share in 2015, and is expected to maintain its dominance during analysis period as well. Read this Research Report here:- – PowerPoint PPT presentation

Number of Views:19

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Male Hypogonadism Market Share, Trends & Forecast - 2022


1
Male Hypogonadism Market
Opportunities and Forecasts, 2014 - 2022
Pages 157 Published 2017
2
 
MALE HYPOGONADISM MARKET
Injectables held the largest market share in
2015. The launch of innovative injectables for
the treatment of hypogonadism in men and rise in
preference for injections of gonadotropin-releasin
g hormones over TRT gels other formulations are
expected to drive growth of this drug delivery
method. Shubhangi Bawakar
3
 
MALE HYPOGONADISM MARKET OVERVIEW
  • Male Hypogonadism Market report, published by
    Allied Market Research forecasts that the global
    market was valued at 2,594 million in 2015, and
    is estimated to reach 3,233 million by 2022,
    growing at a CAGR of 3.1 from 2016 to 2022. 
  • The pituitary disorders segment accounted for
    nearly half of the total market share in 2015,
    and is expected to maintain its dominance during
    analysis period as well.
  • Male hypogonadism is a clinical condition in
    which testes cannot produce enough testosterone,
    resulting in decreased development of muscle
    mass, impaired growth of body hair, development
    of breast tissues, and lack of deepening of the
    voice. 
  • Growth in the male hypogonadism market is driven
    by the rise in prevalence incidence of men with
    testosterone deficiency, increase in infertility
    rates, and growth in awareness among the patient
    population about hypogonadism treatment options
    by certain campaigns carried out by the
    government. 
  • Read more at https//www.alliedmarketresearch.co
    m/male-hypogonadism-market

4
PERCENTAGE OF TOTAL POPULATION AGED 65 YEARS
ABOVE BY COUNTRY
 
5
 
MALE HYPOGONADISM MARKET KEY BENEFITS
  • The study provides an in-depth analysis of the
    market with current trends and future estimations
    to elucidate the imminent investment pockets.
  • It presents a quantitative analysis from 2014 to
    2022, which is expected to enable the
    stakeholders to capitalize on prevailing market
    opportunities.
  • Extensive analysis by therapy helps in
    understanding the various types of therapies used
    to treat hypogonadism.
  • Comprehensive analysis of all geographical
    regions is provided, which assist in determining
    the main opportunities in these geographies.
  • Key players within the market are profiled and
    their strategies are analyzed thoroughly to
    determine the competitive outlook of the global
    market.

6
 
MEXICO MALE HYPOGONADISM MARKET REVENUE
7
 
MALE HYPOGONADISM MARKET KEY FINDINGS
  • By drug therapy, gonadotropin and
    gonadotropin-releasing hormones therapy segment
    is projected to grow at the highest CAGR of 8.9
    during the forecast period.
  • Pituitary disorders segment is expected to grow
    at the CAGR of 3.2.
  • Injectables accounted for nearly half of the
    market share in 2015.
  • North America accounted for majority of the share
    (more than three-fourths) in 2015, and is
    expected to remain dominant throughout the
    forecast period.
  • U.S. accounted for the majority share in the
    North American market in 2015, and the Mexican
    market is expected to grow at the highest CAGR of
    6.7.

8
 
KEY PLAYERS IN INDUSTRY
  • AbbVie Inc.
  • Allergan plc
  • AstraZeneca plc
  • Bayer AG
  • Eli Lilly and Company Ltd.
  • Endo International plc
  • Merck Co., Inc.
  • Ferring Holding S.A.
  • Finox Biotech
  • IBSA Institut Biochimque SA
  • Laboratoires Genevrier
  • Teva Pharmaceutical Industries Ltd.
  • Download Sample Report
  • https//www.alliedmarketresearch.com/request-free-
    sample/1874

9
 
MALE HYPOGONADISM MARKET SEGMENTATION
10
 
MALE HYPOGONADISM MARKET BY GEOGRAPHY
North America Europe Asia-Pacific LAMEA
11
 
 
Thank You! For More Details
Visit us at
https//www.alliedmarketresearch.com/male-hypogona
dism-market
Follow Us On
About PowerShow.com